10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review

      , , , , ,
      Cancers
      MDPI AG

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endocrine therapy forms the backbone of systemic therapy for the majority of persons with early and late-stage breast cancer. However, the side effects can negatively affect quality of life, and impact treatment adherence and overall oncological outcomes. Adverse effects on cognition are common, underreported and challenging to manage. We aim to describe the nature, incidence, risk factors and underlying mechanisms of endocrine therapy-induced cognitive dysfunction. We conducted a comprehensive literature review of the studies reporting on cognitive dysfunction associated with endocrine therapies for breast cancer. We also summarise prevention and treatment strategies, and ongoing research. Given that patients are taking endocrine therapies for longer durations than ever before, it is essential that these side effects are managed pro-actively within a multi-disciplinary team in order to promote adherence to endocrine therapy and improve patients’ quality of life.

          Related collections

          Most cited references86

          • Record: found
          • Abstract: found
          • Article: not found

          Breast Cancer Treatment

          Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

              PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                CANCCT
                Cancers
                Cancers
                MDPI AG
                2072-6694
                February 2022
                February 12 2022
                : 14
                : 4
                : 920
                Article
                10.3390/cancers14040920
                35205665
                f7a8acfe-a350-4371-8abf-202063d3ad47
                © 2022

                https://creativecommons.org/licenses/by/4.0/

                History

                Comments

                Comment on this article